KOSPI
Every company in the roster listed on KOSPI.
Every company in the roster listed on KOSPI.
18 of 18 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Boryung Pharmaceutical003850 · KOSPI | 1 asset: 1 Ph 3 | Fimasartan/atorvastatin/ezetimibe (BR1017)Phase 3 · HypertensionPartial signal | None on record | — | $170MMar 2026 | — | $38M |
Celltrion068270 · KOSPI | 11 assets: 8 approved, 3 Ph 3 | CT-P44Phase 3 · Multiple Myeloma | Feb 2027CT-P51 · Phase 3 | — | $679MDec 2024 | Profitable | — |
Chong Kun Dang Pharmaceutical185750 · KOSPI | 9 assets: 1 approved, 3 Ph 3, 2 Ph 2, 3 Ph 1 | CKD-701Phase 3 · Age-Related Macular DegenerationReliable signal | Dec 2029CKD-703 · Phase 1/2 | — | — | — | — |
Daewoong Pharmaceutical069620 · KOSPI | 7 assets: 4 Ph 3, 2 Ph 1, 1 other | EnavogliflozinPhase 3 · Type 2 DiabetesReliable signal | Nov 2027Enavogliflozin · Phase 3 | — | — | — | $155M |
Dong-A ST170900 · KOSPI | 9 assets: 1 approved, 2 Ph 3, 2 Ph 2, 3 Ph 1, 1 other | EvogliptinPhase 3 · Type 2 DiabetesReliable signal | Dec 2026DA-2811 · Phase 2 | — | — | — | — |
GC Biopharma Corp.006280 · KOSPI | 1 asset: 1 Ph 3 | Hepatitis B immune globulin (I.V.-Hepabig)Phase 3 · Chronic Hepatitis B | None on record | — | — | — | — |
HanAll BioPharma009420 · KOSPI | 2 assets: 1 Ph 3, 1 Ph 1 | ImeroprubartPhase 3 · Myasthenia Gravis | May 2027Imeroprubart · Phase 2 | — | — | — | — |
Handok002390 · KOSPI | 2 assets: 1 approved, 1 Ph 3 | TeneligliptinPhase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
Hanmi Pharmaceutical128940 · KOSPI | 5 assets: 1 Ph 3, 3 Ph 2, 1 Ph 1 | efpeglenatidePhase 3 · ObesityReliable signal | Jan 2027HM15275 · Phase 2 | — | — | — | $161M |
IlDong Pharmaceutical Co., Ltd.249420 · KOSPI | 1 asset: 1 Ph 3 | Besifovir dipivoxil (Besivo)Phase 3 · Chronic Hepatitis BPartial signal | None on record | — | — | — | — |
JW Pharmaceutical001060 · KOSPI | 7 assets: 5 Ph 3, 1 Ph 1, 1 other | AnagliptinPhase 3 · Type 2 DiabetesReliable signal | 31 Mar 2027Anagliptin · Approved | — | — | — | $48M |
Korea United Pharm033270 · KOSPI | 2 assets: 1 Ph 3, 1 Ph 1 | Cilostazol/rosuvastatin (UI022/UI023)Phase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | None on record | — | — | — | — |
Kwang Dong Pharmaceutical009290 · KOSPI | 1 asset: 1 Ph 2 | bremelanotidePhase 2 · ObesityReliable signal | None on record | — | $98MDec 2025 | — | $6.4M |
LG Chem051910 · KOSPI | 4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1 | GemigliptinPhase 3 · Type 2 DiabetesReliable signal | Nov 2027LB-LR1109 · Phase 1 | — | — | — | — |
Prestige Biopharma Limited950210 · KOSPI | 1 asset: 1 Ph 3 | HD204Phase 3 · Non-Small Cell Lung CancerReliable signal | None on record | — | — | — | — |
SK Biopharmaceuticals Co., Ltd.326030 · KOSPI | 3 assets: 2 approved, 1 Ph 3 | CarisbamatePhase 3 · EpilepsyPartial signal | Dec 2026Solriamfetol · Phase 3 | — | — | — | — |
SK Chemicals285130 · KOSPI | 1 asset: 1 other | cilostazol/Ginkgo bilobaAtherosclerotic Cardiovascular Disease | None on record | — | $393MDec 2025 | — | — |
Yuhan Corporation000100 · KOSPI | 7 assets: 1 approved, 1 Ph 3, 2 Ph 2, 3 other | SarpogrelatePhase 3 · Atherosclerotic Cardiovascular Disease | 31 Dec 2026Lazertinib · Phase 1 | — | $241MDec 2025 | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.